|
|
|
| |
| Company Profile |
| |
|
QLT, Inc., a bio-pharmaceutical company, engages in the discovery, development, and commercialization of therapies in the fields of ophthalmology, dermatology, oncology, and urology primarily in North America. The companys products include Visudyne, which is used for the treatment of choroidal neovascularization; and Eligard products that are used for prostate cancer incorporate a leutinizing hormone-releasing hormone agonist, or LHRH agonist, known as leuprolide acetate with its proprietary Atrigel drug delivery system. QLT also offers generic dermatology products, including lidocaine and prilocaine cream, erythromycin and benzoyl peroxide topical gel, mometasone furoate ointment, betamethasone dipropionate cream, and fluticasone propionate cream. In addition, it provides dental products, which include Atridox and Atrisorb-D. The company has strategic alliances with Novartis Ophthalmics. QLT was formed in 1981 and is headquartered in Vancouver, Canada.
|
QLT INC Related |
|
QLT Inc. Develops pharmaceutical products for use in photodynamic therapy (PDT), and other emerging technologies.
|
|
QLT Inc.: Information from Answers.com QLT Inc. (NASDAQ (GS):QLTI) (Toronto:QLT) Company Financials Income Statement Balance Sheet Cash Flow Statement Contact Information QLT Inc
|
|
QLTI: Basic Chart for QLT Inc. - Yahoo! Finance Access the chart for QLT Inc. (QLTI) in line, bar or candlestick type. ... QLT Inc. ( QLTI) On Nov 12: 1.98 0.09 (4.35%) MORE ON QLTI. Quotes. Summary. Real ...
|
|
